Find Fibrinogen manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 89105-94-2, Chembl409436, Fibrinogen-binding inhibitor peptide, Dtxsid10433062, Hishisleuglyglyalalysglnalaglyaspval, Bdbm50034686
Molecular Formula
C50H80N18O16
Molecular Weight
1189.3  g/mol
InChI Key
STSKWZSBFZRSGP-GYDGUXFESA-N

Fibrinogen
1 2D Structure

Fibrinogen

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid
2.1.2 InChI
InChI=1S/C50H80N18O16/c1-24(2)13-33(67-48(81)34(15-29-18-55-23-60-29)66-44(77)30(52)14-28-17-54-22-59-28)45(78)58-19-37(70)56-20-38(71)61-27(6)43(76)64-31(9-7-8-12-51)47(80)65-32(10-11-36(53)69)46(79)62-26(5)42(75)57-21-39(72)63-35(16-40(73)74)49(82)68-41(25(3)4)50(83)84/h17-18,22-27,30-35,41H,7-16,19-21,51-52H2,1-6H3,(H2,53,69)(H,54,59)(H,55,60)(H,56,70)(H,57,75)(H,58,78)(H,61,71)(H,62,79)(H,63,72)(H,64,76)(H,65,80)(H,66,77)(H,67,81)(H,68,82)(H,73,74)(H,83,84)/t26-,27-,30-,31-,32-,33-,34-,35-,41-/m0/s1
2.1.3 InChI Key
STSKWZSBFZRSGP-GYDGUXFESA-N
2.1.4 Canonical SMILES
CC(C)CC(C(=O)NCC(=O)NCC(=O)NC(C)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)N)C(=O)NC(C)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)O)NC(=O)C(CC1=CN=CN1)NC(=O)C(CC2=CN=CN2)N
2.1.5 Isomeric SMILES
C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CN=CN2)N
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. 89105-94-2

2. Chembl409436

3. Fibrinogen-binding Inhibitor Peptide

4. Dtxsid10433062

5. Hishisleuglyglyalalysglnalaglyaspval

6. Bdbm50034686

7. Mfcd00167528

8. Ncgc00167215-01

2.3 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 1189.3 g/mol
Molecular Formula C50H80N18O16
XLogP3-9.7
Hydrogen Bond Donor Count18
Hydrogen Bond Acceptor Count20
Rotatable Bond Count39
Exact Mass1188.59996854 g/mol
Monoisotopic Mass1188.59996854 g/mol
Topological Polar Surface Area547 Ų
Heavy Atom Count84
Formal Charge0
Complexity2310
Isotope Atom Count0
Defined Atom Stereocenter Count9
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Aventacell Biomedical

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Aventacell Biomedical

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

02

Aventacell Biomedical

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Aventacell Biomedical

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

KM Biologics

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

KM Biologics

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

Biotech Showcase
Not Confirmed

02

Biotech Showcase
Not Confirmed
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-moreread-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Human fibrinogen drug substance

Registration Number : 227MF10083

Registrant's Address : 1-6-1 Okubo, Kita-ku, Kumamoto City, Kumamoto Prefecture

Initial Date of Registration : 2015-03-12

Latest Date of Registration : 2016-03-23

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Fibryga is a fibrinogen concentrate which acts as as fibrinogen replacement therapy. It is approved for the treatment of acquired fibrinogen deficiency (AFD).


Lead Product(s): Fibrinogen,Inapplicable

Therapeutic Area: Hematology Brand Name: Fibryga

Study Phase: Approved FDFProduct Type: Protein

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 01, 2024

blank

01

Octapharma

Switzerland
arrow
Biotech Showcase
Not Confirmed

Octapharma

Switzerland
arrow
Biotech Showcase
Not Confirmed

Details : Fibryga is a fibrinogen concentrate which acts as as fibrinogen replacement therapy. It is approved for the treatment of acquired fibrinogen deficiency (AFD).

Product Name : Fibryga

Product Type : Protein

Upfront Cash : Inapplicable

August 01, 2024

blank

Details:

The supplement approvals resulted in new product labeling for Octaplas™, Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, and fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution.


Lead Product(s): Fibrinogen,Inapplicable

Therapeutic Area: Hematology Brand Name: Fibryga

Study Phase: Phase IIIProduct Type: Protein

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 29, 2021

blank

02

Octapharma

Switzerland
arrow
Biotech Showcase
Not Confirmed

Octapharma

Switzerland
arrow
Biotech Showcase
Not Confirmed

Details : The supplement approvals resulted in new product labeling for Octaplas™, Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, and fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution.

Product Name : Fibryga

Product Type : Protein

Upfront Cash : Inapplicable

March 29, 2021

blank

Details:

Octapharma to present multiple clinical trial posters on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use to treat congenital and acquired bleeding disorders.


Lead Product(s): Fibrinogen,Inapplicable

Therapeutic Area: Hematology Brand Name: Fibryga

Study Phase: Approved FDFProduct Type: Protein

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 03, 2020

blank

03

Octapharma

Switzerland
arrow
Biotech Showcase
Not Confirmed

Octapharma

Switzerland
arrow
Biotech Showcase
Not Confirmed

Details : Octapharma to present multiple clinical trial posters on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use to treat congenital and acquired bleeding disorders.

Product Name : Fibryga

Product Type : Protein

Upfront Cash : Inapplicable

December 03, 2020

blank

Details:

Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Afibrinogenemia.


Lead Product(s): Fibrinogen,Inapplicable

Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Protein

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 19, 2020

blank

04

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Afibrinogenemia.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

November 19, 2020

blank
  • Development Update

Details:

Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.


Lead Product(s): Fibrinogen,Prothrombin Complex Concentrate

Therapeutic Area: Hematology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Protein

Sponsor: Sunnybrook Health Sciences Centre | Octapharma | Canadian Institutes of Health Research | Canadian Institute for Military and Veteran Health Research Defense Research & Development Canada

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 01, 2020

blank

05

University Health Network, Toronto

Country
arrow
Biotech Showcase
Not Confirmed

University Health Network, Toronto

Country
arrow
Biotech Showcase
Not Confirmed

Lead Product(s) : Fibrinogen,Prothrombin Complex Concentrate

Therapeutic Area : Hematology

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : Sunnybrook Health Sciences Centre | Octapharma | Canadian Institutes of Health Research | Canadian Institute for Military and Veteran Health Research Defense Research & Development Canada

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

September 01, 2020

blank
  • Development Update

Details:

Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Huntington Disease.


Lead Product(s): Fibrinogen,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Protein

Sponsor: Octapharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 06, 2020

blank

06

University of Virginia

Country
arrow
Biotech Showcase
Not Confirmed

University of Virginia

Country
arrow
Biotech Showcase
Not Confirmed

Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Huntington Disease.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

May 06, 2020

blank
  • Development Update

Details:

Riastap (Fibrinogen) is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Postpartum Hemorrhage.


Lead Product(s): Fibrinogen,Inapplicable

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Riastap

Study Phase: Phase I/ Phase IIProduct Type: Protein

Sponsor: CSL Behring

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 19, 2015

blank

07

Yale University

Country
arrow
Biotech Showcase
Not Confirmed

Yale University

Country
arrow
Biotech Showcase
Not Confirmed

Details : Riastap (Fibrinogen) is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Postpartum Hemorrhage.

Product Name : Riastap

Product Type : Protein

Upfront Cash : Inapplicable

August 19, 2015

blank
  • Development Update

Details:

Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wounds and Injuries.


Lead Product(s): Fibrinogen,Inapplicable

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Protein

Sponsor: CSL Behring

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 22, 2015

blank

08

Rigshospitalet

Country
arrow
Biotech Showcase
Not Confirmed

Rigshospitalet

Country
arrow
Biotech Showcase
Not Confirmed

Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wounds and Injuries.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

January 22, 2015

blank
  • Development Update

Details:

Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Wounds and Injuries.


Lead Product(s): Fibrinogen,Inapplicable

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Protein

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 30, 2014

blank

09

Sunnybrook Health Sciences Centre

Country
arrow
Biotech Showcase
Not Confirmed

Sunnybrook Health Sciences Centre

Country
arrow
Biotech Showcase
Not Confirmed

Details : Fibrinogen is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Wounds and Injuries.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

July 30, 2014

blank

Details:

Thrombin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.


Lead Product(s): Thrombin,Fibrinogen

Therapeutic Area: Hematology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Undisclosed

Sponsor: Johnson & Johnson

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 24, 2014

blank

10

Ethicon

U.S.A
arrow
Biotech Showcase
Not Confirmed

Ethicon

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : Thrombin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

March 24, 2014

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Human Fibrinogen

Brand Name : Tisseel

Dosage Form : POW

Dosage Strength : 72-110mg/ml

Packaging : 2X1mg/ml

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

blank

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Human Fibrinogen

Brand Name : Tisseel

Dosage Form : POW

Dosage Strength : 72-110mg/ml

Packaging : 4X1mg/ml

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

blank

03

CSL Behring

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

CSL Behring

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Human Fibrinogen

Brand Name : Riastap

Dosage Form : Powder For Solution For Injection And Infusion

Dosage Strength : 1G

Packaging :

Approval Date : 2017-01-19

Application Number :

Regulatory Info : Authorised

Registration Country : Malta

blank

04

Octapharma

Switzerland
BIO Partnering at JPM
Not Confirmed
arrow

Octapharma

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Human Fibrinogen

Brand Name : Fibryga

Dosage Form : Powder And Solvent For Injectable Solution And Infusion

Dosage Strength : 20MG/ML

Packaging :

Approval Date : 2022-08-10

Application Number :

Regulatory Info : Authorised

Registration Country : Malta

blank

05

Country
BIO Partnering at JPM
Not Confirmed
arrow

Country
arrow
BIO Partnering at JPM
Not Confirmed

Fibrinogen, human, Thrombin, human

Brand Name : TachoSil

Dosage Form : Registration for the future

Dosage Strength : 5.5 mg/cm2/2 IE/cm2

Packaging : Boks 5 7.5cm2

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

06

Country
BIO Partnering at JPM
Not Confirmed
arrow

Country
arrow
BIO Partnering at JPM
Not Confirmed

Fibrinogen, human, Thrombin, human

Brand Name : TachoSil

Dosage Form : Registration for the future

Dosage Strength : 5.5 mg/cm2/2 IE/cm2

Packaging : Boks 1 45.6cm2

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

07

Country
BIO Partnering at JPM
Not Confirmed
arrow

Country
arrow
BIO Partnering at JPM
Not Confirmed

Fibrinogen, human, Thrombin, human

Brand Name : TachoSil

Dosage Form : Registration for the future

Dosage Strength : 5.5 mg/cm2/2 IE/cm2

Packaging : Boks 1 7.5cm2

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

08

Country
BIO Partnering at JPM
Not Confirmed
arrow

Country
arrow
BIO Partnering at JPM
Not Confirmed

Fibrinogen, human, Thrombin, human

Brand Name : TachoSil

Dosage Form : Registration for the future

Dosage Strength : 5.5 mg/cm2/2 IE/cm2

Packaging : Boks 1 23cm2

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

09

Country
BIO Partnering at JPM
Not Confirmed
arrow

Country
arrow
BIO Partnering at JPM
Not Confirmed

Fibrinogen, human, Thrombin, human

Brand Name : TachoSil

Dosage Form : Registration for the future

Dosage Strength : 5.5 mg/cm2/2 IE/cm2

Packaging : Boks 2 23cm2

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies
In 2024, the biopharma industry continued to advance on its robust trajectory of innovation. Though the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) approved fewer drugs, there was a significant increase in medical breakthroughs.While the CDER approved 50 new drugs in 2024, as compared to 55 in 2023, the CBER granted 14 biologics approvals in 2024, down from 20 in 2023.The European Medicines Agency (EMA) approved 34 new therapies, up from 32 in 2023, while Health Canada granted 28 approvals, down from 38 in 2023.The year saw long-awaited treatments being approved in areas such as schizophrenia and Alzheimer’s disease in the second half (H2) of 2024. In H1 2024, drugs to treat metabolic dysfunction-associated steatohepatitis (MASH) and chronic obstructive pulmonary disease (COPD) had been granted FDA approvals.As the year drew to a close, FDA began approving drugs at a feverish pace, with 29 of the CDER’s 50 approvals coming in H2.Like most years, the landscape of drug approvals was dominated by oncology, with 15 of the 50 drugs (30 percent) approved targeting various forms of cancer. This was followed by dermatology and non-malignant hematology, each accounting for 12 percent of approvals. Notably, small molecules continued to dominate the market, making up for 64 percent of the new drug approvals, while 32 percent were proteins, including monoclonal and bi-specific antibodies. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available)Karuna-BMS’ schizophrenia drug, Lilly’s Alzheimer’s med, Neurocrine’s Crenessity dominate list of pathbreaking approvals in H2Out of the 50 new drugs approved in 2024, CDER identified 24 (48 percent) as first-in-class, showcasing novel mechanisms of action. The most anticipated approval of 2024 was Karuna and Bristol Myers Squibb’s Cobenfy, a groundbreaking treatment for schizophrenia. This fixed-dose combination of xanomeline and trospium chloride represents the first novel mechanism of action in decades for this debilitating psychiatric condition. Analysts forecast peak annual sales of over US$ 3.3 billion for Cobenfy. Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) became the third amyloid-targeting antibody to gain FDA approval. Unlike its predecessors, Kisunla offers a unique limited-duration treatment regimen, allowing patients to discontinue therapy once amyloid levels in the brain drop below a certain threshold. Priced at approximately US$ 32,000 per year, it is positioned as a cost-effective alternative to existing treatments. Analysts estimate peak sales of US$ 2.4 billion for Kisunla.Crenessity (crinecerfont), developed by Neurocrine Biosciences, became the first FDA-approved treatment in decades for classic congenital adrenal hyperplasia (genetic conditions that affect the adrenal glands). Similarly, Vertex’s triple combination therapy of deutivacaftor, tezacaftor & vanzacaftor (Alyftrek) for cystic fibrosis represents a significant advancement in genetic disease treatment. Analysts forecast peak sales exceeding US$ 8.3 billion, underscoring the therapy’s potential to transform patient care.Meanwhile, Bridgebio’s Attruby (acoramidis hydrochloride) emerged as a promising treatment for cardiac amyloidosis, a life-threatening condition. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Roche’s Itovebi, Checkpoint’s Unloxcyt clinch FDA approvals in H2 2024; forecast to achieve blockbuster statusThe dominance of cancer drug approvals reflects the ongoing focus on targeted therapies, immuno-oncology, and precision medicine to improve outcomes for patients with hard-to-treat cancers.Among the year’s notable FDA approvals was Genentech’s Itovebi (inavolisib), another targeted therapy that treats hormone receptor-positive (HR+), HER2-negative breast cancer. Itovebi is a PI3Kα inhibitor designed specifically for patients with PIK3CA mutations, a common driver of resistance to endocrine therapy in breast cancer. It demonstrated a more tolerable safety profile. Roche projects Itovebi’s peak (annual) sales to reach CHF 2 billion (US$ 2.3 billion).Checkpoint Therapeutics’ Unloxcyt (cosibelimab) joined the crowded checkpoint inhibitor market as the eleventh PD-1/PD-L1-targeting monoclonal antibody approved by the FDA. It was granted approval for cutaneous squamous cell carcinoma (cSCC), an aggressive form of skin cancer with high recurrence rates. As compared to other checkpoint inhibitors, like Keytruda (pembrolizumab) and Opdivo (nivolumab), Unloxcyt is likely to offer an advantage in immune activation.FDA also approved Astellas’ Vyloy (zolbetuximab), a first-in-class monoclonal antibody for metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Analysts forecast peak sales of approximately US$ 850 million for Vyloy.Syndax Pharmaceuticals’ Revuforj (revumenib) was approved by FDA to treat a type of acute leukemia in both adults and children. This approval introduces a novel class of medications known as menin inhibitors. These agents are currently in clinical development for the treatment of genetically defined subsets of acute leukemia. These inhibitors function by preventing the activation of cancer growth-related proteins. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Potential blockbusters Lilly’s Ebglyss, Galderma’s Nemluvio lead advances in dermatologyEli Lilly’s Ebglyss (lebrikizumab) garnered significant attention. Approved by FDA for moderate-to-severe atopic dermatitis, this monoclonal antibody introduces a less burdensome dosing regimen compared to its competitors, with maintenance therapy required only once a month. This feature positions it as a potential contender to Dupixent (dupilumab), a market leader in atopic dermatitis. Ebglyss sales are forecast to reach US$ 1.9 billion by 2030.Galderma’s Nemluvio (nemolizumab) secured FDA approval for two indications in 2024 — prurigo nodularis (a chronic disorder of the skin) and moderate-to-severe atopic dermatitis in patients aged 12 years and older. As the first humanized IgG2 monoclonal antibody targeting the IL-31 receptor, Nemluvio directly inhibits the key driver of itch and inflammation in both these conditions. With its unique mechanism and broad dermatology potential, analysts forecast peak sales of approximately US$ 1.66 billion. Ebglyss and Nemluvio underscore the growing importance of biologics in dermatological care.Botanix Pharmaceuticals also made strides in dermatology by clinching an FDA approval for Sofdra (sofpironium) in June. The drug has been okayed for the treatment of primary axillary hyperhidrosis, a condition characterized by excessive sweating.Ascendis Pharma’s Yorvipath (palopegteriparatide), a therapy approved by FDA to treat hypoparathyroidism, is forecast to achieve blockbuster sales of US$ 1.8 billion by 2030, highlighting its potential to transform endocrine care. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Our viewOverall, 2024 was defined by its breakthrough drug approvals. The year also saw significant reduction in complete response letters (CRLs) — they dropped from 43 in 2023 to just 29 in 2024. This suggests improved industry preparedness and alignment with regulatory expectations.The new year began with the approval of Datroway (datopotamab deruxtecan) from AstraZeneca and Daiichi Sankyo, marking a significant advancement in oncology. Several other promising new drugs are coming up for FDA approval this year, such as J&J’s nipocalimab, Vertex Pharmaceuticals’ suzetrigine, Elevar Therapeutics’ rivoceranib/camrelizumab, Sanofi’s fitusiran and GSK’s gepotidacin. Hopefully, the momentum of breakthrough approvals will continue through 2025, political headwinds in the US notwithstanding. 

Impressions: 11822

https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies

#PharmaFlow by PHARMACOMPASS
30 Jan 2025

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Regulatory FDF Prices

read-more
read-more

01

Brand Name : TachoSil

Country
arrow
BIO Partnering at JPM
Not Confirmed

Brand Name : TachoSil

Country
arrow
BIO Partnering at JPM
Not Confirmed

Fibrinogen

Dosage Form : Registration for the future

Dosage Strength : 5.5 mg/cm2/2 IE/cm2

Price Per Pack (Euro) : 248.11

Published in :

Country : Norway

RX/OTC/DISCN :

blank

02

Brand Name : TachoSil

Country
arrow
BIO Partnering at JPM
Not Confirmed

Brand Name : TachoSil

Country
arrow
BIO Partnering at JPM
Not Confirmed

Fibrinogen

Dosage Form : Registration for the future

Dosage Strength : 5.5 mg/cm2/2 IE/cm2

Price Per Pack (Euro) : 214.24

Published in :

Country : Norway

RX/OTC/DISCN :

blank

03

Brand Name : TachoSil

Country
arrow
BIO Partnering at JPM
Not Confirmed

Brand Name : TachoSil

Country
arrow
BIO Partnering at JPM
Not Confirmed

Fibrinogen

Dosage Form : Registration for the future

Dosage Strength : 5.5 mg/cm2/2 IE/cm2

Price Per Pack (Euro) : 49.62

Published in :

Country : Norway

RX/OTC/DISCN :

blank

04

Brand Name : TachoSil

Country
arrow
BIO Partnering at JPM
Not Confirmed

Brand Name : TachoSil

Country
arrow
BIO Partnering at JPM
Not Confirmed

Fibrinogen

Dosage Form : Registration for the future

Dosage Strength : 5.5 mg/cm2/2 IE/cm2

Price Per Pack (Euro) : 170.44

Published in :

Country : Norway

RX/OTC/DISCN :

blank

05

Brand Name : TachoSil

Country
arrow
BIO Partnering at JPM
Not Confirmed

Brand Name : TachoSil

Country
arrow
BIO Partnering at JPM
Not Confirmed

Fibrinogen

Dosage Form : Registration for the future

Dosage Strength : 5.5 mg/cm2/2 IE/cm2

Price Per Pack (Euro) : 249.29

Published in :

Country : Norway

RX/OTC/DISCN :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Tachosil

Human Thrombin, Human Fibrogen

arrow
Biotech Showcase
Not Confirmed

Brand Name : Tachosil

Japan
arrow
Biotech Showcase
Not Confirmed

Human Thrombin, Human Fibrogen

Main Therapeutic Indication :

Currency : USD

2016 Revenue in Millions : Not Reported

2015 Revenue in Millions : 40

Growth (%) : -100

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

Health Canada Patents

read-more
read-more

01

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

FIBRINOGEN (HUMAN), THROMBIN (HUMAN), COLLAGEN

Brand Name : TACHOSIL

Patent Number : 2434964

Filing Date : 2002-01-25

Strength per Unit : (9.5 cm x 4.8 cm) per cm?: 5.5 mg / 2.0 IU & 2.1mg

Dosage Form : PATCH

Human Or VET : Human

Route of Administration : TOPICAL

Patent Expiration Date : 2022-01-25

Date Granted : 2009-04-21

blank

02

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

FIBRINOGEN (HUMAN), THROMBIN (HUMAN), COLLAGEN

Brand Name : TACHOSIL

Patent Number : 2434964

Filing Date : 2002-01-25

Strength per Unit : (4.8 cm x 4.8 cm) per cm?: 5.5 mg / 2.0 IU & 2.1 m

Dosage Form : PATCH

Human Or VET : Human

Route of Administration : TOPICAL

Patent Expiration Date : 2022-01-25

Date Granted : 2009-04-21

blank

03

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

FIBRINOGEN (HUMAN), THROMBIN (HUMAN), COLLAGEN

Brand Name : TACHOSIL

Patent Number : 2434964

Filing Date : 2002-01-25

Strength per Unit : (3.0 cm x 2.5 cm) per cm?: 5.5 mg, 2.0 IU & 2.1 mg

Dosage Form : PATCH

Human Or VET : Human

Route of Administration : TOPICAL

Patent Expiration Date : 2022-01-25

Date Granted : 2009-04-21

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 89105-94-2 / Fibrinogen API manufacturers, exporters & distributors?

Fibrinogen manufacturers, exporters & distributors 1

68

PharmaCompass offers a list of Fibrinogen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fibrinogen manufacturer or Fibrinogen supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fibrinogen manufacturer or Fibrinogen supplier.

PharmaCompass also assists you with knowing the Fibrinogen API Price utilized in the formulation of products. Fibrinogen API Price is not always fixed or binding as the Fibrinogen Price is obtained through a variety of data sources. The Fibrinogen Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Fibrinogen

Synonyms

89105-94-2, Chembl409436, Fibrinogen-binding inhibitor peptide, Dtxsid10433062, Hishisleuglyglyalalysglnalaglyaspval, Bdbm50034686

Cas Number

89105-94-2

Fibrinogen Manufacturers

A Fibrinogen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fibrinogen, including repackagers and relabelers. The FDA regulates Fibrinogen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fibrinogen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Fibrinogen Suppliers

A Fibrinogen supplier is an individual or a company that provides Fibrinogen active pharmaceutical ingredient (API) or Fibrinogen finished formulations upon request. The Fibrinogen suppliers may include Fibrinogen API manufacturers, exporters, distributors and traders.

click here to find a list of Fibrinogen suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Fibrinogen USDMF

A Fibrinogen DMF (Drug Master File) is a document detailing the whole manufacturing process of Fibrinogen active pharmaceutical ingredient (API) in detail. Different forms of Fibrinogen DMFs exist exist since differing nations have different regulations, such as Fibrinogen USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Fibrinogen DMF submitted to regulatory agencies in the US is known as a USDMF. Fibrinogen USDMF includes data on Fibrinogen's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fibrinogen USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Fibrinogen suppliers with USDMF on PharmaCompass.

Fibrinogen JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Fibrinogen Drug Master File in Japan (Fibrinogen JDMF) empowers Fibrinogen API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Fibrinogen JDMF during the approval evaluation for pharmaceutical products. At the time of Fibrinogen JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Fibrinogen suppliers with JDMF on PharmaCompass.

Fibrinogen GMP

Fibrinogen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Fibrinogen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fibrinogen GMP manufacturer or Fibrinogen GMP API supplier for your needs.

Fibrinogen CoA

A Fibrinogen CoA (Certificate of Analysis) is a formal document that attests to Fibrinogen's compliance with Fibrinogen specifications and serves as a tool for batch-level quality control.

Fibrinogen CoA mostly includes findings from lab analyses of a specific batch. For each Fibrinogen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Fibrinogen may be tested according to a variety of international standards, such as European Pharmacopoeia (Fibrinogen EP), Fibrinogen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fibrinogen USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty